Reference(s)
Click here to return to the Reference Table

Category: Carcinomas
Cancer type: Prostate
Descriptor: Therapeutic Development


Reference Number: 221
Davies, G. et al. The HGF/SF antagonist NK4 reverses fibroblast- and HGF-induced prostate tumor growth and angiogenesis in vivo. Int J Cancer 106:348-54 (2003).
PubMed link      E-mail link

Reference Number: 293
Davies G, Watkins G, Mason MD, Jiang WG. Targeting the HGF/SF receptor c-met using a hammerhead ribozyme transgene reduces in vitro invasion and migration in prostate cancer cells. Prostate 60, 317-24 (2004)
PubMed link      E-mail link

Reference Number: 345
Shinomiya N, Gao CF, Xie Q, Gustafson M, Waters DJ, Zhang YW, Vande Woude GF. RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival. Cancer Res64, 7962-70 (2004)
PubMed link      E-mail link

Reference Number: 386
Hashem M, Essam T. Hepatocyte growth factor as a tumor marker in the serum of patients with prostate cancer. J Egypt Natl Canc Inst. 17, 114-20 (2005)
PubMed link      E-mail link

Reference Number: 505
Ye L, Lewis-Russell JM, Davies G, Sanders AJ, Kynaston H, Jiang WG. Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells. Int J Oncol. 30, 521-9 (2007)
PubMed link      E-mail link

Reference Number: 688
Gupta A, Karakiewicz PI, Roehrborn CG, Lotan Y, Zlotta AR, Shariat SF. Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer. Clin Cancer Res. 14, 7385-90 (2008)
PubMed link      E-mail link

Reference Number: 705
Fan S, Meng Q, Laterra JJ, Rosen EM. Role of Src signal transduction pathways in scatter factor-mediated cellular protection. J Biol Chem. 284, 7561-77 (2009) Epub 2008 Dec 1
PubMed link      E-mail link

Reference Number: 728
Dai Y, Siemann DW. BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro. Mol Cancer Ther. 9, 1554-61 (2010)
PubMed link      E-mail link

Reference Number: 936
Tu WH, Zhu C, Clark C, Christensen JG, Sun Z. Efficacy of c-Met inhibitor for advanced prostate cancer. BMC Cancer. 10, 556 (2010)
PubMed link      E-mail link

Reference Number: 942
McLarty J, Bigelow RL, Smith M, Elmajian D, Ankem M, Cardelli JA. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev Res (Phila). 2, 673-82 (2009)
PubMed link      E-mail link

Reference Number: 1042
Aftab DT, McDonald DM. MET and VEGF: synergistic targets in castration-resistant prostate cancer. Clin Transl Oncol. 13, 703-9 (2011)
PubMed link      E-mail link

Reference Number: 1107
Elnagar AY, Sylvester PW, El Sayed KA. (-)-Oleocanthal as a c-Met inhibitor for the control of metastatic breast and prostate cancers. Planta Med. 77, 1013-9 (2011)
PubMed link      E-mail link

Reference Number: 1123
Chang HY, Kao MC, Way TD, Ho CT, Fu E. Diosgenin suppresses hepatocyte growth factor (HGF)-induced epithelial-mesenchymal transition by down-regulation of Mdm2 and vimentin. J Agric Food Chem. 59, 5357-63 (2011)
PubMed link      E-mail link

Reference Number: 1209
Varkaris A, Corn PG, Gaur S, Dayyani F, Logothetis CJ, Gallick GE. The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs. 20, 1677-84 (2011)
PubMed link      E-mail link

Reference Number: 1222
Dai Y, Siemann DW. Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607. BMC Cancer. 12, 198 (2012)
PubMed link      E-mail link

Reference Number: 1298
Saylor PJ, Armstrong AJ, Fizazi K, Freedland S, Saad F, Smith MR, Tombal B, Pienta K. New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol. 63, 309-20 (2013)
PubMed link      E-mail link

Reference Number: 1326
Ryan CJ, Rosenthal M, Ng S, Alumkal J, Picus J, Gravis G, Fizazi K, Forget F, Machiels JP, Srinivas S, Zhu M, Tang R, Oliner KS, Jiang Y, Loh E, Dubey S, Gerritsen WR. Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin Cancer Res. 19, 215-24 (2013)
PubMed link      E-mail link

Reference Number: 1510
Nguyen HM, Ruppender N, Zhang X, Brown LG, Gross TS, Morrissey C, Gulati R, Vessella RL, Schimmoller F, Aftab DT, Corey E. Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling. PLoS One. 8, e78881 (2013)
PubMed link      E-mail link

Reference Number: 1572
Nguyen HM, Ruppender N, Zhang X, Brown LG, Gross TS, Morrissey C, Gulati R, Vessella RL, Schimmoller F, Aftab DT, Corey E. Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling. PLoS One. 8, :e78881 (2013)
PubMed link      E-mail link